Skip to content
2000
Volume 12, Issue 5
  • ISSN: 1568-0266
  • E-ISSN: 1873-4294

Abstract

This short review tells the story of how Reversed Chloroquine drugs (RCQs) were developed. These are hybrid molecules, made by combining the quinoline nucleus from chloroquine (CQ) with moieties which are designed to inhibit efflux via known transporters in the membrane of the digestive vacuole of the malaria parasite. The resulting RCQ drugs can have potencies exceeding that of CQ, while at the same time having physical chemical characteristics that may make them favorable as partner drugs in combination therapies. The need for such novel antimalarial drugs will continue for the foreseeable future.

Loading

Article metrics loading...

/content/journals/ctmc/10.2174/156802612799362968
2012-03-01
2025-05-06
Loading full text...

Full text loading...

/content/journals/ctmc/10.2174/156802612799362968
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test